FLINT, Mich., March 16, 2017 /PRNewswire/ -- Diplomat
Pharmacy, Inc. (NYSE: DPLO), will dispense KISQALI®
(ribociclib) as a first-line treatment for postmenopausal women
with a serious form of breast cancer.
The Food and Drug Administration recently approved
KISQALI® as a once-daily oral therapy for use in
combination with an aromatase inhibitor. It is for postmenopausal
women who have advanced or metastatic breast cancer that is hormone
receptor–positive and human epidermal growth factor receptor
2–negative.
To learn more about Diplomat's oncology program, visit
diplomat.is/areas-of-excellence/oncology.
"The diagnosis of advanced or metastatic breast cancer has a
devastating impact on patients, as well as their loved ones," said
Paul Urick, Diplomat president.
"KISQALI® is a groundbreaking new treatment that can
improve quality of life for our patients."
According to the American Cancer Society, breast cancer is the
second most common cancer among American women, with more than
315,000 diagnoses expected in 2017.
For full prescribing information, click here.
Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements give
current expectations or forecasts of future events or our future
financial or operating performance. The forward-looking
statements contained in this press release are based on
management's good-faith belief and reasonable judgment based on
current information. These statements are qualified by
important risks and uncertainties, many of which are beyond our
control, that could cause our actual results to differ materially
from those forecasted or indicated by such forward-looking
statements. For a discussion of such risks and uncertainties, you
should review Diplomat's filings with the Securities and Exchange
Commission, including "Risk Factors" in Diplomat's Annual Report on
Form 10-K for the year ended Dec. 31,
2016, and in subsequent reports filed with or furnished to
the Securities and Exchange Commission. Except as may be
required by any applicable laws, Diplomat assumes no obligation to
publicly update such forward-looking statements, which are made as
of the date hereof or the earlier date specified herein, whether as
a result of new information, future developments or otherwise.
About Diplomat
Diplomat (NYSE: DPLO) serves patients and physicians in all 50
states. Headquartered in Flint,
Michigan, the company focuses on medication management
programs for people with complex chronic diseases. Diplomat opened
its doors in 1975 as a neighborhood pharmacy with one essential
tenet: "Take good care of patients and the rest falls into place."
Today, that tradition continues—always focused on improving patient
care and clinical adherence. For more information, visit
diplomat.is.
CONTACT:
Kali Lucas,
Public Relations Specialist
810.768.9580 | press@diplomat.is
Gary Rice, RPh, MS, MBA, CSP
Executive Vice President of Operations
810.768.9863 | grice@diplomat.is
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/diplomat-to-dispense-kisqali-for-metastatic-breast-cancer-300425161.html
SOURCE Diplomat Pharmacy, Inc.